GlassScriptPhysician profile
Parag A Majmudar
NPI 1912988981
$450,702.86
in general payments reported to CMS, 2019-2025
39 companies · $112K in 2025
The $112K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125K · 2020: $14K · 2021: $47K · 2022: $38K · 2023: $61K · 2024: $54K · 2025: $112K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $94K · Consulting Fee: $78K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Travel and Lodging: $13K · Food and Beverage: $12K · Gift: $36.06 · Honoraria: $32.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $94,081.25 |
| Consulting Fee | $77,637.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,690.00 |
| Travel and Lodging | $12,894.06 |
| Food and Beverage | $12,380.77 |
| Gift | $36.06 |
| Honoraria | $32.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $110,654.17 | 2022-2025 | Miebo, Xiidra, Crystalens Accommodating Iol (At-52ao) |
| Dompe US, INC. | $53,287.62 | 2019-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $49,430.19 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Alcon Vision LLC | $49,113.99 | 2019-2025 | Tryptyr, Acrysof Iq Panoptix Uv Iol, Acrysof Iq Vivity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $43,320.89 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $39,785.54 | 2019-2022 | |
| Shire North American Group INC | $28,105.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22,323.07 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $16,141.16 | 2019-2023 | Tobradex St |
| Alcon Research LLC | $11,700.00 | 2022-2025 | Tryptyr |
| Carl Zeiss Meditec, INC. | $8,722.10 | 2019-2025 | Quatera 700, Veracity Surgical, Visumax |
| Glaukos Corporation | $3,451.48 | 2021-2025 | Kxl System (Not Refurbished), Ce-Marked Kxla System, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Allergan, INC. | $2,980.06 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $2,020.58 | 2020 | |
| Biotissue Holdings INC. | $1,535.88 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,501.64 | 2020-2024 | Ifs Advanced Femtosec Laser, Compact Intuitiv, Tecnis Iol |
| Carl Zeiss Meditec USA, INC. | $1,432.13 | 2021-2025 | Visumax, Cirrus Hd-Oct, Veracity Surgical |
| Topcon Healthcare, INC. | $1,345.09 | 2024-2025 | |
| Abbvie INC. | $922.30 | 2022-2025 | |
| Harrow Eye, LLC | $630.56 | 2024-2025 | Vevye, Triesence |
| Rxsight INC | $613.12 | 2023-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece |
| Ocular Therapeutix, INC. | $457.44 | 2019-2020 | |
| Oyster Point Pharma, INC. | $367.33 | 2022-2024 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $133.79 | 2024 | Xdemvy |
| Merck Sharp & Dohme LLC | $127.76 | 2025 | Capvaxive |
| Haag-Streit USA, INC. | $107.03 | 2024 | |
| New World Medical,INC. | $104.50 | 2021-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Quidel Corporation | $87.88 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $74.98 | 2022-2025 | Acthar |
| Aerie Pharmaceuticals, INC. | $39.11 | 2020 | |
| Lensar, INC. | $29.38 | 2025 | Lensar Laser System |
| Kowa Research Institute, INC. | $27.27 | 2023 | |
| Ivantis, INC | $26.80 | 2020 | |
| Lumibird Medical INC. | $25.45 | 2025 | |
| Horizon Therapeutics Plc | $23.29 | 2021 | |
| Tearlab Corp | $19.54 | 2022 | |
| Rayner Intraocular Lenses Limited | $18.14 | 2022 | |
| Eyepoint US, INC. | $16.41 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$300,144.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parag Majmudar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.